

# Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among $V\alpha 24^+V\beta 11^+$ NKT cell subsets with distinct cytokine-producing capacity

Chang H. Kim, Brent Johnston, and Eugene C. Butcher

Natural killer T (NKT) cells are important regulators of the immune system, but their trafficking machinery, including expression of chemokine receptors, has been poorly defined. Unlike other conventional T-cell populations, we show that most NKT cells express receptors for extralymphoid tissue or inflammation-related chemokines (CCR2, CCR5, and CXCR3), while few NKT cells express lymphoid tissue-homing chemokine receptors (CCR7 and CXCR5). A population with homing potential for lymph nodes (L selectin<sup>+</sup> CCR7<sup>+</sup>) exists only within a small subset of CD4 NKT cells. We show

differential expression of chemokine receptors among NKT cell subsets: CCR4 is mainly expressed by a high cytokine (interleukin-4/interleukin-2)-producing (CD4) NKT subset, while CCR1, CCR6, and CXCR6 are preferentially expressed by the low cytokine-producing CD8 and CD4<sup>-</sup>CD8<sup>-</sup> subsets. In line with this, TARC/CCL17 (a CCR4 ligand) induces preferential chemotaxis of the CD4 NKT subset, while chemotactic activities of LARC/CCL20 (a CCR6 ligand) and MIP-1 $\alpha$ /CCL3 (a CCR1 ligand) are focused on the CD8 and CD4<sup>-</sup>CD8<sup>-</sup> NKT cells. We conclude that, unlike conventional naive,

memory, or effector T cells, the entire NKT cell population expresses nonlymphoid tissue homing chemokine receptors, yet NKT cell subsets differ considerably from each other by displaying distinct and reciprocal expression patterns of some chemokine receptors. Our results identify chemokine receptors that are potentially important for trafficking of human blood NKT cell subsets and reveal their function (cytokine production capacity)-dependent differential trafficking potentials. (*Blood*. 2002;100:11-16)

© 2002 by The American Society of Hematology

## Introduction

Natural killer T (NKT) cells constitute a unique class of T-lymphocyte lineage that shares some characteristics with NK cells.<sup>1,2</sup> These cells have an extremely restricted T-cell receptor (TCR) repertoire, consisting of an invariant  $V\alpha 24$ -J $\alpha$ Q chain preferentially paired with a  $V\beta 11$  chain in human beings.<sup>3,4</sup> Although their natural TCR ligands remain to be identified, NKT cells can be generated and activated by glycolipid antigens such as  $\alpha$ -galactosylceramide and glycosyl-phosphatidylinositol in the context of CD1d, a  $\beta_2$ -microglobulin-associated major histocompatibility complex class I-like molecule.<sup>5-7</sup>

Human NKT cells express NK-associated NKR-P1 (CD161, the human version of mouse NK1.1) and CD45RO and are heterogeneous in expression of CD4 or CD8.<sup>8-11</sup> NKT cells, especially the CD4<sup>+</sup> subset, are enriched in type 2 (interleukin-4<sup>+</sup> [IL-4<sup>+</sup>]) and type 0 (IL-4<sup>+</sup> interferon- $\gamma$ <sup>+</sup> [IFN- $\gamma$ <sup>+</sup>]) cells.<sup>11-13</sup> NKT cells with distinct cytokine production profiles can be generated by different types of dendritic cells or stimuli.<sup>14</sup> Efficient production of cytokines, particularly IL-4, is important for the regulation of the immune system by inhibition of Th1 and induction of Th2 response. NKT cells have also been implicated in tumor rejection, control of microbial infection, suppression of autoimmune diseases, and graft-versus-host disease after bone marrow transplantation.<sup>1,2,15</sup>

NKT cells are widely distributed in the body, including bone marrow, liver, thymus, lymph nodes, spleen, and lung.<sup>2</sup> Whereas thymus and liver contain primarily CD1d-dependent NKT cells, spleen and bone marrow are enriched in CD1d-independent NKT cells, suggesting differential localization of CD1d-dependent NKT cells from other related T-cell types in mice.<sup>16</sup> NKT cells found in different organs or tissues are heterogeneous in production of cytokines.<sup>13,16</sup> Chemokines, differentially expressed in tissue and inflammatory microenvironments, guide homing and localization of leukocytes in the body by inducing adhesion and chemotaxis through various cell surface chemokine receptors.<sup>17-20</sup> Thus, we postulated that chemokine receptor expression patterns of NKT cell subsets may be distinct from other T-cell subsets to allow their differential tissue localization.

We examined chemokine response and receptor expression by different human  $V\alpha 24^+V\beta 11^+$  NKT cell subsets in circulation. We show that most NKT cells express tissue-homing chemokine receptors and that NKT cell subsets with different cytokine production potentials display distinctive chemokine receptor expression patterns and chemokine responses, differing from each other and from the conventional T cells. We conclude that NKT cells are specialized both in cytokine production and expression of chemokine receptors.

From the Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, CA; and Center for Molecular Biology and Medicine, Veterans Affairs Palo Alto Health Care System, CA.

Submitted December 7, 2001; accepted February 28, 2002. Prepublished online as *Blood* First Edition Paper April 17, 2002; DOI 10.1182/blood-2001-12-0196.

Supported by a special fellowship from the Leukemia and Lymphoma Society (C.H.K.); grants AI47822, GM37734, and AI37832 from the National Institutes

of Health; an award from the Department of Veterans Affairs (E.C.B.); and the FACS Core facility of the Stanford Digestive Disease Center.

**Reprints:** Chang H. Kim, 3801 Miranda Ave, Mail code 154-B, VAMC Building 101, Room C4-111, Palo Alto, CA 94304; e-mail: chkim@stanford.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

## Materials and methods

### Reagents

Antibodies to IFN- $\gamma$  (4S.B3), IL-2 (MQ1-17H12), IL-5 (JES1-39D10), CD161 (DX12), CD4 (RPA-T4), CD45RA (HI100), and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) (Mab11) were purchased from Pharmingen (San Diego, CA). Antibodies to CD8 (3B5) and CD56 (MEM-188) were from Caltag (Burlingame, CA). Antibodies to CLA (HECA 452) and CD62L (DREG-200) were from our laboratory. Anti-IL4 (3010.211) was from Becton Dickinson (Mountain View, CA). Antibodies to CCR1 (53504.111) CCR2 (48607.121), CCR5 (45549.111), CCR6 (53103.111), CXCR3 (49801.111), CXCR6 (56 811.111), and CXCR5 (51505.111) were from R&D Systems (Minneapolis, MN). Antibodies to  $\alpha$ 4 $\beta$ 7 (Act-1), CCR3 (7B11), CCR4 (1G1), CCR7 (7H12-12-2), and CCR9 (GPR96-1) were from Millennium Pharmaceuticals (Cambridge, MA). Human chemokines, thymus and activation-regulated chemokine (TARC), interferon  $\gamma$  inducible protein-10 (IP-10), B lymphocyte chemoattractant (BLC), I-309, EBI-1–ligand chemokine (ELC), and macrophage-inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ) were from R&D Systems. Human liver and activation-regulated chemokine (LARC) was from PeproTech (Rocky Hill, NJ). All antibodies to chemokine receptors have been tested on positive control cells. The anti-CCR3 used in this study binds to eosinophils.<sup>21</sup> The anti-CCR9 used in this study binds to naive and memory T cells.<sup>22</sup> The batches of each antibody used in the current study were shown to react with eosinophils or gut homing lymphocyte subsets as well.

### NKT cell preparation

For NKT cell sources, unseparated peripheral blood mononuclear cells (for chemokine receptor analysis) (Stanford University Blood Center) or isolated V $\beta$ 11<sup>+</sup> T cells were used (for chemotaxis and cytokine analysis). Peripheral blood mononuclear cells were prepared by density gradient centrifuge on Histopaque-1077 (Sigma, St Louis, MO). TCR V $\beta$ 11<sup>+</sup> T cells were isolated with anti-V $\beta$ 11–biotin and streptavidin beads and sorted by a magnetic method (V $\beta$ 11<sup>+</sup> cells > 99%, Miltenyi Biotec, Auburn, CA).

### Chemokine receptor expression


Peripheral blood mononuclear cells were sequentially stained with anti-CKR, antimouse immunoglobulin G (IgG)–biotin and streptavidin-allophycocyanin plus anti-V $\alpha$ 24–fluorescein isothiocyanate (FITC), anti-V $\beta$ –11–phycoerythrin, and other antibodies to various surface antigens (eg, CD4, CD8, CD56, CD161). One million cells were acquired for each fluorescence-activated cell sorter analysis. Isotype-matched mouse antibodies (IgG1, IgG2a, and IgG2b) were used to control the chemokine receptor expression. Antibodies to CCR1, CCR2, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5, and CXCR6 are IgG2a. Antibodies to CCR4, CCR5, and CXCR3 are IgG1. Anti-CCR3 is IgG2b. All isotype (IgG1, IgG2a, and IgG2b) control antibodies did not stain NKT cells (not shown). Negative controls shown in Figures 1 and 2 were with IgG2b.

### Chemotaxis

Chemotaxis assays were performed as previously described.<sup>23</sup> Isolated TCR V $\beta$ 11<sup>+</sup> T cells were used as input cells for chemotaxis. A total of  $2 \times 10^5$  to  $5 \times 10^5$  cells were used per Transwell (Corning, Cambridge, MA) and allowed to chemotax for 3 hours. Chemokines TARC, LARC, MIP-1 $\alpha$ , ELC, BLC, IP-10, MCP-1, MIP-1 $\beta$ , and I-309 were used at indicated concentrations. After chemotaxis, migrated cells in bottom wells were collected and stained with anti-V $\alpha$ 24–FITC, anti-CD4, and anti-CD8. Numbers of migrated cells and input cells were counted using FACSCalibur (Becton Dickinson), and the percent migrated cells of each cell subset was calculated.


### Intracellular cytokine production analyses

Intracellular cytokine analyses have been performed as previously described.<sup>24</sup> Briefly, isolated TCR V $\beta$ 11<sup>+</sup> T cells were stained with anti-V $\alpha$ 24–FITC, anti-CD4–allophycocyanin, and anti-CD8–TriColor and activated for 4 hours with phorbol myristate acetate (50 ng/mL) and ionomycin (1  $\mu$ M) in the presence of monensin (Sigma). Activated T cells were fixed and permeabilized with Cytotfix/perme solution (Pharmingen), followed by staining with phycoerythrin-conjugated monoclonal antibodies to cytokines (IL-4, IL-15, IL-10, IL-13, IFN- $\gamma$ , and TNF- $\alpha$ ). Stained cells were analyzed



**Figure 1. Expression of chemokine receptors by human NKT cells in circulation.** (A) Phenotype and frequency ( $n = 33$ ) of human NKT cells examined in this study. (B) Chemokine receptor expression by V $\alpha$ 24<sup>+</sup> V $\beta$ 11<sup>+</sup> NKT cells, CD4 (naive CD45RA<sup>+</sup> and memory CD45RA<sup>-</sup>), and CD8 (naive CD45RA<sup>+</sup> CD27<sup>+</sup>, memory CD45RA<sup>-</sup> CD27<sup>+</sup>, and effector CD45RA<sup>+</sup> CD27<sup>-</sup>) T-cell subsets. Different symbols represent data from different donors, and horizontal bars represent averages (NKT cells, the upper left panel). Results from 6 donors (NKT cells) or averages  $\pm$  SD from 4 donors (CD4 and CD8 T-cell subsets) are shown. (C) Chemokine receptor expression by V $\alpha$ 24<sup>+</sup> V $\beta$ 11<sup>+</sup> NKT cells shown as dot plots. Percentages positive are shown in parentheses.

**Figure 2. Distinct expression pattern of chemokine receptors among NKT cell subsets.** (A) Chemokine receptor expression by CD4, CD8, and DN NKT subsets (n = 4). (B) Dot plots of chemokine receptor expression by NKT cell subsets with percentages positive. (C) Relative frequencies of CD4, CD8, and DN NKT cell subsets in the  $V\alpha 24^+ V\beta 11^+$  NKT cell population (n = 11). (D) Differential cytokine production capacities of NKT cell subsets (n = 5). Isolated  $V\beta 11^+$  NKT cells were stained with antibodies to  $V\alpha 24$ , CD4, and CD8 and activated with phorbol myristate acetate and ionomycin in the presence of monensin to block internalization of surface antigens followed by intracellular cytokine analyses. Bars indicate averages of results from 4 (A), 11 (C), or 5 (D) donors. \*Significant differences from the CD4 NKT subset ( $P < .05$  [A,D]). \*\*Significant difference from CD4 or CD8 subset ( $P < .02$  [C]).



with FACSCalibur and CellQuest program (Becton Dickinson). Only viable cells based upon their forward and side scatter were gated for cytokine analyses.

### Statistics

Comparisons were performed by analysis of variance, and significant differences between groups were tested using a paired Student *t* test. Statistical significance was set at  $P < .05$ .

## Results

### Chemokine receptor expression by $V\alpha 24^+ V\beta 11^+$ NKT cells


$V\alpha 24^+ V\beta 11^+$  NKT cells represent a very small population in blood (on average 0.089% of lymphocytes, n = 33) (Figure 1A). Almost all of these circulating NKT cells express CD161, while only a subset expresses CD56 (Figure 1A). We examined  $V\alpha 24^+ V\beta 11^+$  NKT cells for expression of a panel of chemokine receptors. CCR1, a receptor expressed by few T cells, is expressed by about 60% of NKT cells (Figure 1B,C). Most NKT cells also express CCR2, CCR5, CCR6, CXCR3, and CXCR6. These chemokine receptors are expressed by T cells with homing potential to nonlymphoid tissues and are highly associated with inflammation.<sup>25</sup> Almost all express CXCR4, a receptor also widely expressed by T, B, and monocytes. Few NKT cells express CCR3, CCR9, and CXCR5, which are mainly expressed by eosinophils (CCR3),<sup>21</sup> thymocytes and gut homing lymphocytes (CCR9),<sup>22</sup> or B cells and a subset of follicle homing CD4 T cells (CXCR5).<sup>23,26</sup> CCR7, a chemokine receptor important for T-cell homing into lymphoid tissues,<sup>27-29</sup> is expressed by only 10% to 28% (n = 6) of NKT cells. CCR4, a receptor implicated in lymphocyte homing to skin<sup>30</sup> and expressed on most IL-4–producing CD4 T cells,<sup>31</sup> is expressed by about 11% of NKT cells. Although the chemokine receptor expression pattern of NKT cells is somewhat similar to that of CD45RA<sup>−</sup>CD27<sup>+</sup> CD8 T cells, a larger percentage of NKT cells express CCR1, CCR2, CCR6, and CXCR6 compared with this CD8 T-cell subset (Figure 1B,C). Despite the distinct expression pattern of chemokine receptors by NKT cells, it is notable that there

are considerable variations among donors in the fraction of NKT cells expressing each chemokine receptor (Figure 1B).

### Chemokine receptor expression by NKT cell subsets

Based upon expression of CD4 and/or CD8, 3 subsets of NKT cells, CD4<sup>+</sup>CD8<sup>−</sup> (CD4), CD4<sup>−</sup>CD8<sup>+</sup> (CD8), and CD4<sup>−</sup>CD8<sup>−</sup> (DN), can be identified. The relative frequency of each subset differs considerably from person to person (Figure 2C). On average, 49% of  $V\alpha 24^+ V\beta 11^+$  cells are DN, 27% are CD4, and 24% are CD8 NKT cells (n = 12). The wide variation in frequency of NKT cells expressing each chemokine receptor (Figure 1B) may be related to this variation of NKT cell subset composition and prompted us to individually examine chemokine receptor expression by each NKT cell subset. CCR1 is expressed by few cells of the CD4 subset but by most CD8 and DN cells (Figure 2A,B). Slightly, but consistently, more DN (than CD8) cells express CCR1. In a similar manner, CCR6 and CXCR6 are also preferentially expressed by DN and CD8 subsets. CCR2, CCR5, and CXCR3 are expressed by most of each NKT subset with slight differences (DN  $\geq$  CD8  $\geq$  CD4). In contrast, CCR4 is mainly expressed by the CD4 subset but by few cells in the CD8 or DN subset. There is no notable difference in expression of CCR7 among the NKT cell subsets. Thus, some receptors, CCR4 (CD4) and CCR1, CCR6 and CXCR6 (DN and CD8), are characteristically and differentially expressed by NKT cell subsets.

It has been reported that human CD4<sup>+</sup> NKT cells contain many more Th0-like cells producing IL-4 and IFN- $\gamma$  than CD4<sup>−</sup> NKT cells.<sup>11</sup> Here we examined the differences in cytokine production capacity among the CD4, CD8, and DN NKT subsets that display different chemokine receptor expression patterns. As previously reported, CD4 NKT cells were far better than other subsets in producing IL-4. CD8 NKT cells are slightly but consistently better than DN cells in producing IL-4 (Figure 2D). Notably, the 3 NKT cell subsets are very different also in production of IL-2. No significant difference was observed among the NKT cell subsets in producing IFN- $\gamma$  and TNF- $\alpha$ . Thus, the CD4 NKT cell subset contains most of the IL-2– and IL-4–producing NKT cells in circulation, while CD8 and DN NKT cells contain relatively few such cells.



**Figure 3. Differential chemokine responses among NKT cell subsets.** (A) Chemotactic responses of CD4, CD8, and DN NKT cell subsets. Cell migration is shown as net migration after subtraction of background migration. (B) Frequency of IL-2-, IL-4-, and IFN- $\gamma$ -producing NKT cells in chemotaxed cells after migration to TARC or LARC. Chemokines were used at the indicated concentration (A) or 250 ng/mL (TARC) and 1500 ng/mL (LARC) for panel B. Chemotaxed NKT cells were phenotyped by surface and/or intracellular cytokine staining followed by counting. Relative frequencies of cytokine producers were calculated by dividing numbers of cytokine-producing NKT cells after chemotaxis by those NKT cells in input (input = 1, marked by horizontal lines [B]). \*Significant differences ( $P < .05$ ) between CD4 and CD8 or DN NKT subsets ( $n = 4$ , [A]) or the 2 groups ( $n = 6$  [B]).

### Chemokine responses of NKT cell subsets

We examined the chemotactic response of NKT cell subsets to chemokines. MIP-1 $\alpha$  (a CCR1 ligand) induced good chemotaxis of CD8 and DN NKT cells but poor chemotaxis of CD4 cells (Figure 3A). LARC (a CCR6 ligand) induced robust chemotaxis of CD8 and DN NKT cells but low chemotaxis of CD4 cells. In contrast, TARC (a CCR4 ligand) induced significant CD4 NKT cell migration but did not attract DN and CD8 NKT cells well. ELC (a CCR7 ligand) induced migration of all 3 subsets at similar levels. SDF-1 (the CXCR4 ligand), MCP-1 (a CCR2 ligand), and IP-10 (a CXCR3 ligand) attracted all 3 NKT cell subsets very well (Figure 3A), while BLC (the CXCR5 ligand), thymus-expressed chemokine (TECK) (the CCR9 ligand), and I-309 (a CCR8 ligand) did not show any notable chemotactic activity for NKT cells (not shown).

To further examine whether chemokines can differentially enrich cytokine producers versus nonproducers after chemotaxis, the frequencies of IL-2-, IL-4-, and IFN- $\gamma$ -producing NKT cells were compared to the input population after chemotaxis to TARC and LARC (Figure 3B). IL-2 and IL-4 producers were enriched in TARC-attracted, but not LARC-attracted, NKT cells. However, no considerable enrichment or depletion was observed for IFN- $\gamma$  producers after chemotaxis to these chemokines. Thus, NKT cell subsets with distinct cytokine-producing capacities display differential responses to chemokines, and their chemokine response correlates well with the chemokine receptor expression pattern.

### Expression of other homing receptors by NKT cell subsets

Along with chemokine receptors, adhesion molecules such as CD62L, CLA, and  $\alpha 4\beta 7$  are important for tissue-specific homing of leukocytes. CD62L is implicated in homing to peripheral lymph nodes, and it has been reported that human NKT cells are CD62L<sup>low/-</sup>.<sup>9,10</sup> To migrate into T-cell areas of lymph nodes, cells are thought to also coexpress CCR7.<sup>27-29</sup> Thus, we examined the existence of CD62L<sup>+</sup>CCR7<sup>+</sup> NKT cells in circulation (Table 1). A small but distinct CD62L<sup>+</sup>CCR7<sup>+</sup> subset is found within the NKT cell population. Most of these CD62L<sup>+</sup>CCR7<sup>+</sup> NKT cells are CD4<sup>+</sup>, a few are DN, and virtually none are CD8<sup>+</sup>. Many NKT cells (60%-90%,  $n = 4$ ) express a gut homing receptor,  $\alpha 4\beta 7$  (Table 1); this frequency is higher than that among conventional CD4 memory T cells (20%-30% are  $\alpha 4\beta 7$ <sup>+</sup>). Expression of CLA, a skin homing receptor, is also detected on a subset (on average 7%-13%,  $n = 4$ ) of NKT cells. Whereas CLA and  $\alpha 4\beta 7$  are largely mutually exclusive among conventional CD4 cells, many CLA<sup>+</sup> NKT cells coexpress  $\alpha 4\beta 7$  (not shown).

### Discussion

Here we examined expression of chemokine receptors and homing receptors by a unique T-cell subset, V $\alpha$ 24<sup>+</sup>V $\beta$ 11<sup>+</sup> "NKT" cells. The definition of NKT cells is controversial, especially in mice, because not all CD1d-restricted cells express NK1.1 and some NK1.1<sup>+</sup> T cells are not CD1d-restricted. Surrogate markers such as CD56 and CD161 do not specifically identify human NKT cells either, because few NKT cells express CD56, and non-NKT T cells can express CD56 and CD161 (Figure 1A). In human beings, identification with antibodies to TCR V $\alpha$ 24 and V $\beta$ 11<sup>4,11</sup> or binding with  $\alpha$ -galactosylceramide-loaded CD1d tetramers<sup>32,33</sup> appears to be the most specific way to identify NKT cells. Our results reveal existence not only of unique chemokine receptor expression patterns by NKT cells but also differential expression of trafficking machinery among NKT cell subsets.

Our finding of differential chemokine receptor expression patterns correlates with the wide distribution of NKT cells in tissues. Most NKT cells express CCR1, CCR2, CCR5, CXCR3, CXCR4, and CXCR6. Among these, CCR1, CCR2, CCR5, CXCR3, and CXCR6 are highly associated with "tissue" T cells found in extralymphoid tissues.<sup>24,25,34</sup> Their chemokine ligands (eg, MIP-1 $\alpha$ , MCP-1, MIP-1 $\beta$ , IP-10) are widely expressed in extralymphoid tissues and up-regulated by inflammatory signals. Furthermore, most NKT cells also express  $\alpha 4\beta 7$ , a homing receptor to gut-associated lymphoid systems. In contrast, CCR7, a receptor required for homing into lymphoid tissues and expressed by all naive T cells and many (about 70%) memory T cells, is expressed by only about 20% of NKT cells; the follicular homing receptor, CXCR5, is expressed by few NKT cells. Thus, the chemokine receptor expression pattern suggests that, unlike naive and memory T cells, most NKT cells have the machinery to localize in extralymphoid tissues, and only a small subset of NKT cells have a homing potential to secondary lymphoid tissues. NKT cells lack the expression of CXCR5, the chemokine receptor needed to

**Table 1. Frequencies (%) of L selectin<sup>+</sup> CCR7<sup>+</sup>, CLA<sup>+</sup>, and  $\alpha 4\beta 7$ <sup>+</sup> cells in each NKT cell subset in circulation**

NKT cell subsets	L selectin <sup>+</sup> CCR7 <sup>+</sup>	CLA <sup>+</sup>	$\alpha 4\beta 7$ <sup>+</sup>
CD4	3.9 $\pm$ 2.2	7 $\pm$ 4.4	63.1 $\pm$ 9.7
CD8	0.2 $\pm$ 0.3	5.6 $\pm$ 4.8	75.9 $\pm$ 13.2
DN	1.3 $\pm$ 0.7	13.4 $\pm$ 4.2	74.1 $\pm$ 16.1

Averages and SDs from 4 different donors are shown.

localize in the B-cell area of lymphoid tissues,<sup>35</sup> and thus are likely to be excluded from the B-cell areas including germinal centers.

Whether blood NKT cells recirculate through peripheral lymph nodes remains unknown. In this regard, it is not clear whether the small number of NKT cells found in lymph nodes are generated in lymph nodes or migrate into the nodes via the afferent lymph or the blood. Our results show that a small population of NKT cells in circulation expresses both CCR7 and L selectin and resides mainly within the CD4 NKT subset. L selectin and CCR7 mediate adhesive interactions of leukocytes and high endothelial venules for transmigration into lymphoid tissues, and CCR7 is required for T cells to localize in T-cell areas of lymphoid tissues in response to CCR7 ligands SLC and ELC. These chemokines are expressed by high endothelial venules (SLC, ELC) and mature DCs in T-cell areas (ELC). Therefore, the small population of NKT cells expressing CCR7 and L selectin can potentially migrate into sites of T-cell differentiation in secondary lymphoid organs.

Interestingly, NKT cell subsets differ substantially in their expression of some chemokine receptors even though NKT cell subsets share expression of many chemokine receptors as discussed above. Most notably, CD4 NKT cells (high IL-2 and IL-4 producers) express CCR4 and are highly responsive to TARC, while CD8 and DN NKT cell subsets (low IL-2 and IL-4 producers) express CCR1, CCR6, and CXCR6 and respond very well to their ligands such as MIP-1 $\alpha$  and LARC. Thus, our results show polarization in chemokine receptor expression and chemokine response among NKT cell subsets with distinct effector functions. It has been reported that chemokine receptors are associated with the effector cytokine production capacity of CD4 or CD8 T cells.<sup>36-38</sup> CCR4 is expressed by almost all IL4-producing CD4 cells, while CXCR3 is expressed by almost all IFN- $\gamma$ -producing cells.<sup>31</sup> T cells expressing CCR2, CCR5, and CXCR6 also contain many more IFN- $\gamma$  producers than total memory T cells.<sup>31</sup> Our results suggest that NKT cells also show such differential expression pattern of chemokine receptors. In the case of NKT cells, however, the association is somewhat skewed by the unusually uniform expression of tissue homing chemokine receptors: Most NKT cells express the Th1-associated chemokine receptors (CCR2, CCR5, and CXCR3) in a less discriminatory way, while they express CCR1, CCR4, CCR6, and CXCR6 more differentially.

Tissue expression of chemokines provides insights into how NKT cells establish tissue tropisms. For example, the chemokine ligand of CCR6, a receptor expressed by the most NKT cells, is LARC, a chemokine mainly expressed in liver among various

tissues.<sup>39</sup> This is in good correlation with the enrichment of NKT cells in liver. Cytokines and inflammatory signals profoundly change the expression pattern of cytokines. Expression of LARC and  $\beta$ -defensin (a nonchemokine CCR6 ligand) in epithelial cells or keratinocytes is greatly enhanced by bacterial endotoxin, IL-1, and TNF- $\alpha$ .<sup>40,41</sup> CCR4 ligands, TARC and MDC, are constitutively detected in thymus at high levels and in small intestine and lung at lower levels.<sup>34,42</sup> Importantly, expression of TARC and MDC is induced by Th2 cytokines IL-4 and/or IL-13 in various cell types<sup>43,44</sup> and in inflamed skin venules,<sup>30</sup> amplifying the recruitment of CCR4<sup>+</sup> T cells to sites of Th2 inflammation. The CXCR6 ligand, CXCL16, is expressed in liver and lung at high levels and in spleen and lymph nodes at low levels.<sup>45</sup> Thus, depending on the expression of 2 types of chemokines (TARC vs LARC, MIP-1 $\alpha$ , and CXCL16) under normal and inflammatory conditions, recruitment of each NKT cell subset may be specifically controlled. Some differences in tissue localization have been observed at least in mice: There are more DN and CD8 than CD4 NKT cells in lungs, while the CD4 subset is the major NKT cell population in thymus.<sup>13</sup> Although chemokine receptor expression and NKT cell localization in tissues could differ in human beings and mouse, our results suggest a potential mechanism to fine-control migration (or retention) of different NKT cell subsets.

In conclusion, our results show that NKT cells almost universally express inflammatory lymphocyte chemokine receptors to levels that are much higher than any other memory or effector T-cell subsets examined and yet display distinct and subset-specific expression profiles of other chemokine receptors, including CCR4 (by CD4), CXCR6, CCR1, and CCR6 (by CD8 and DN). Furthermore, expression of human immunodeficiency virus coreceptors (CCR2, CCR5, CXCR4, and CXCR6) by many CD4 NKT cells suggests that they are potential targets of human immunodeficiency virus infection. The precise NKT cell subset-specific localization in various human tissues in normal and inflammatory conditions remains unknown. Therefore, this report on expression of chemokine and homing receptors would be valuable in helping explain and predict the localization of the circulating human NKT cell subsets.

## Acknowledgment

We thank Dr Lijun Wu (Millennium Pharmaceuticals) for reagents (anti-CCR4 and CCR7).

## References

- Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. *Immunol Today*. 2000;21:573-583.
- Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. *Annu Rev Immunol*. 1997;15:535-562.
- Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-  $\alpha/\beta$  T cells demonstrates preferential use of several V  $\beta$  genes and an invariant TCR  $\alpha$  chain. *J Exp Med*. 1993;178:1-16.
- Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V  $\alpha$  24-J  $\alpha$  Q/V  $\beta$  11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. *J Exp Med*. 1994;180:1171-1176.
- Joyce S, Woods AS, Yewdell JW, et al. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. *Science*. 1998;279:1541-1544.
- Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of  $\nu\alpha$ 14 NKT cells by glycosylceramides. *Science*. 1997;278:1626-1629.
- Schofield L, McConville MJ, Hansen D, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. *Science*. 1999;283:225-229.
- Exley M, Porcelli S, Furman M, Garcia J, Balk S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V  $\alpha$  24 J  $\alpha$  Q T cell receptor  $\alpha$  chains. *J Exp Med*. 1998;188:867-876.
- van Der Vliet HJ, Nishi N, de Grujil TD, et al. Human natural killer T cells acquire a memory-activated phenotype before birth. *Blood*. 2000;95:2440-2442.
- D'Andrea A, Goux D, De Lalla C, et al. Neonatal invariant V $\alpha$ 24<sup>+</sup> NKT lymphocytes are activated memory cells. *Eur J Immunol*. 2000;30:1544-1550.
- Prussin C, Foster B. TCR V  $\alpha$  24 and V  $\beta$  11 co-expression defines a human NK1 T cell analog containing a unique Th0 subpopulation. *J Immunol*. 1997;159:5862-5870.
- Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. *J Exp Med*. 1994;179:1285-1295.
- Hammond KJ, Pelikan SB, Crowe NY, et al. NKT cells are phenotypically and functionally diverse. *Eur J Immunol*. 1999;29:3768-3781.
- Kadowaki N, Antonenko S, Ho S, et al. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. *J Exp Med*. 2001;193:1221-1226.
- Taniguchi M, Nakayama T. Recognition and function of V $\alpha$ 14 NKT cells. *Semin Immunol*. 2000;12:543-550.

16. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. *J Immunol*. 1999;162:6410-6419.
17. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. *Adv Immunol*. 1999;72:209-253.
18. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. *Science*. 1999;286:2098-2102.
19. Baggiolini M. Chemokines and leukocyte traffic. *Nature*. 1998;392:565-568.
20. Kim CH, Broxmeyer HE. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. *J Leukoc Biol*. 1999;65:6-15.
21. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. *J Clin Invest*. 1997;99:178-184.
22. Zabel BA, Agace WW, Campbell JJ, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. *J Exp Med*. 1999;190:1241-1256.
23. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Sub-specialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. *J Exp Med*. 2001;193:1-10.
24. Kim CH, Kunkel EJ, Boisvert J, et al. Bonzo/CXCR6 defines polarized Type 1 T cell subsets with extra-lymphoid tissue homing potential. *J Clin Invest*. 2001;107:595-601.
25. Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. *N Engl J Med*. 1998;338:436-445.
26. Forster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. *Blood*. 1994;84:830-840.
27. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. *Cell*. 1999;99:23-33.
28. Warnock RA, Campbell JJ, Dorf ME, Matsuzawa A, McEvoy LM, Butcher EC. The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. *J Exp Med*. 2000;191:77-88.
29. Stein JV, Rot A, Luo Y, et al. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6CKine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. *J Exp Med*. 2000;191:61-76.
30. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. *Nature*. 1999;400:776-780.
31. Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T cell polarization in vivo. *J Clin Invest*. 2001;108:1331-1339.
32. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. *J Exp Med*. 2000;192:741-754.
33. Kronenberg M, Naidenko O, Koning F. Right on target: novel approaches for the direct visualization of CD1-specific T cell responses. *Proc Natl Acad Sci U S A*. 2001;98:2950-2952.
34. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. *J Biol Chem*. 1996;271:21514-21521.
35. Cyster JG, Ansel KM, Reif K, et al. Follicular stromal cells and lymphocyte homing to follicles. *Immunol Rev*. 2000;176:181-193.
36. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med*. 1998;187:129-134.
37. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. *Int Immunol*. 1999;11:81-88.
38. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. *J Exp Med*. 1998;187:875-883.
39. Hieshima K, Imai T, Opendakker G, et al. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. *J Biol Chem*. 1997;272:5846-5853.
40. Tanaka Y, Imai T, Baba M, et al. Selective expression of mammalian defensins and cathelicidins in intestinal epithelium in mice and humans. *Eur J Immunol*. 1999;29:633-642.
41. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37). *J Leukoc Biol*. 2001;69:691-697.
42. Godiska R, Chantray D, Raport CJ, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. *J Exp Med*. 1997;185:1595-1604.
43. Kumagai N, Fukuda K, Nishida T. Synergistic effect of TNF- $\alpha$  and IL-4 on the expression of thymus- and activation-regulated chemokine in human corneal fibroblasts. *Biochem Biophys Res Commun*. 2000;279:1-5.
44. Andrew DP, Chang MS, McNinch J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. *J Immunol*. 1998;161:5027-5038.
45. Wilbanks A, Zondlo SC, Murphy K, et al. Expression cloning of the stf133/bonzo/tymstr ligand reveals elements of cc, cxc, and cx3c chemokines. *J Immunol*. 2001;166:5145-5154.



**blood**<sup>®</sup>

2002 100: 11-16

doi:10.1182/blood-2001-12-0196 originally published online  
April 17, 2002

## **Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V $\alpha$ 24<sup>+</sup>V $\beta$ 11<sup>+</sup> NKT cell subsets with distinct cytokine-producing capacity**

Chang H. Kim, Brent Johnston and Eugene C. Butcher

---

Updated information and services can be found at:  
<http://www.bloodjournal.org/content/100/1/11.full.html>

Articles on similar topics can be found in the following Blood collections  
[Chemokines, Cytokines, and Interleukins](#) (564 articles)  
[Immunobiology and Immunotherapy](#) (5703 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>